The introduction of VEGF‐targeted agents has improved outcomes in
mRCC
0.7
0.8
0.9
1.0
viving
Patients
Alive
‡
C t ki
th
396
48
2015
3
TT era
100
80
(%)
Favourable
Intermediate
Poor
Intermediategroup: HR=1.89 (95% CI 1.33–2.68)
Poor group:HR=5.73 (95% CI 3.99–8.23)
p<0.0001
0.1
0.2
0.3
0.4
0.5
0.6
Proportion sur
y o ne erapy
Chemotherapy
274
9
2000
*
1
cytokine era
mOS:
13 months
†
mOS since start of
2
nd
line therapy:
12.5 months
60
40
20
Overall survival
Median OS
according to risk
(MSKCC criteria
1
)
Favourable: 27 months
Intermediate: 12 months
Poor: 6 months
0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Years after systemic therapy
Favourable 76
52
31
19
8
1
Intermediate 529
257
97
37
9
4
Poor 261
49
9
3
1
0
0
12
24
36
48
60
0
Months since second-line therapy initiation
Number at risk
2013
*
2
TT era
100
80
60
survival (%)
Favourable
Intermediate
Poor
Log-rank p<0.0001
2016
4
TT era
1.00
0.75
0.50
function
p<0.0001
Risk
mOS, Mo (95%
CI)
n
Favourable
29.9
(19.1–64.3)
40
Intermediate
15.5
(13.0–17.7)
362
Poor
5.5
(4.6–6.9)
152
mOS since start of
1
st
line therapy:
18.8 months
0
12
24
36
48
60
40
20
0
Overall
mOS since start of
3
rd
line therapy:
12.4 months
0
10
50
60
70
80
0.25
0.00
20
30
40
Survival
1. Motzer
et al. Clin Oncol
2000; 2. Heng
et al. Lancet Oncol
2013; 3. Ko
et al
.
Lancet Oncol
2015; 4. Wells
et al. Eur Urol
2016
Median OS
according to risk
(Heng’s criteria
2
)
Favourable: 43.2 months
Intermediate: 22.5 months
Poor: 7.8 months
Time since start of treatment (months)
Overall survival (months)
